Medication-related osteonecrosis of the jaw (MRONJ) caused by bisphosphonates (BPs) and denosumab (Dmab) is still a major oral adverse event caused by cancer treatment and may be under-recognized by private dental services. With the aim of reducing the prevalence of MRONJ, this study, which is a pilot study for a planned future large-scale survey, compared knowledge about MRONJ between dental hygienists (DHs) in private dental clinics and those in cancer center hospitals. We conducted a questionnaire-based survey regarding MRONJ between 1 November 2023 and 31 January 2024 on DHs at a cancer base hospital and a private clinic in Saitama, Japan. We statistically analyzed the data collected using the χ test or Fisher's exact test with the level of significance set at 5%. This study included 10 in-hospital and 53 private clinic DHs. The in-hospital DHs had appropriate knowledge of MRONJ. However, compared with the in-hospital DHs, although the private clinic DHs knew that BPs are used for osteoporosis, significantly fewer had knowledge of Dmab ( < .001) or knew that BPs and Dmab could also be used to treat cancer (both < .001). In addition, few private clinic DHs were aware of MRONJ cases refractory to antibiotic treatment alone ( = .012). These findings suggest that private clinic DHs have less knowledge of MRONJ than those in cancer base hospitals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528679 | PMC |
http://dx.doi.org/10.1177/23337214241292794 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!